User profiles for Raman Sharma
Raman SharmaPGIMER Chandigarh Verified email at pgimer.edu.in Cited by 517 |
Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria
…, RK Amewu, SC Leung, R Sharma… - Proceedings of the …, 2012 - National Acad Sciences
There is an urgent need for new antimalarial drugs with novel mechanisms of action to deliver
effective control and eradication programs. Parasite resistance to all existing antimalarial …
effective control and eradication programs. Parasite resistance to all existing antimalarial …
Clinical characteristics and differential clinical diagnosis of novel coronavirus disease 2019 (COVID-19)
R Sharma, M Agarwal, M Gupta, S Somendra… - … Disease 2019 (COVID …, 2020 - Springer
Novel Coronavirus Disease (COVID-19) has become a rapidly growing pandemic involving
several nations. It is of serious concern and extreme challenge not only to the health …
several nations. It is of serious concern and extreme challenge not only to the health …
Highly selective inhibition of human CYP3A in vitro by azamulin and evidence that inhibition is irreversible
…, T Ho, CE Cargill, AP Blanchard, R Sharma… - Drug Metabolism and …, 2004 - ASPET
Azamulin [14-O-(5-(2-amino-1,3,4-triazolyl)thioacetyl)-dihydromutilin] is an azole derivative
of the pleuromutilin class of antiinfectives. We tested the inhibition potency of azamulin …
of the pleuromutilin class of antiinfectives. We tested the inhibition potency of azamulin …
Clinical profile of Covid-19 infected patients admitted in a tertiary care hospital in North India.
…, S Sharma, P Keshwani, R Sharma… - The Journal of the …, 2020 - europepmc.org
Background The novel coronavirus (Covid-19) continues to wreck havoc across China,
European countries, USA and now seems to gain a strong foothold in India. The aim of this report …
European countries, USA and now seems to gain a strong foothold in India. The aim of this report …
Identification, Design and Biological Evaluation of Bisaryl Quinolones Targeting Plasmodium falciparum Type II NADH:Quinone Oxidoreductase (PfNDH2)
…, SC Leung, NG Berry, R Sharma… - Journal of medicinal …, 2012 - ACS Publications
A program was undertaken to identify hit compounds against NADH:ubiquinone oxidoreductase
(PfNDH2), a dehydrogenase of the mitochondrial electron transport chain of the malaria …
(PfNDH2), a dehydrogenase of the mitochondrial electron transport chain of the malaria …
Antisense oligonucleotides: modifications and clinical trials
There has been an upsurge in the number of clinical trials involving chemically modified
oligonucleotide-based drug candidates after the FDA approval of Vitravene, Macugen, and …
oligonucleotide-based drug candidates after the FDA approval of Vitravene, Macugen, and …
Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance
AC Rand, SSF Leung, H Eng, CJ Rotter, R Sharma… - …, 2012 - pubs.rsc.org
A series of cyclic peptides were designed and prepared to investigate the physicochemical
properties that affect oral bioavailabilty of this chemotype in rats. In particular, the ionization …
properties that affect oral bioavailabilty of this chemotype in rats. In particular, the ionization …
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl) …
…, TH Lin, BS Pierce, E Saiah, R Sharma… - Journal of medicinal …, 2018 - ACS Publications
Cytokine signaling is an important characteristic of autoimmune diseases. Many pro-inflammatory
cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of …
cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of …
The impact of incinerators on human health and environment
Of the total wastes generated by health-care organizations, 10%–25% are biomedical wastes,
which are hazardous to humans and the environment and requires specific treatment and …
which are hazardous to humans and the environment and requires specific treatment and …
Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects
Z Miao, G Nucci, N Amin, R Sharma, V Mascitti… - Drug Metabolism and …, 2013 - ASPET
The disposition of ertugliflozin (PF-04971729), an orally active selective inhibitor of the
sodium-dependent glucose cotransporter 2, was studied after a single 25-mg oral dose of [ 14 C]-…
sodium-dependent glucose cotransporter 2, was studied after a single 25-mg oral dose of [ 14 C]-…